Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
October 17, 2018 07:00 ET
|
Aeglea BioTherapeutics, Inc.
Pegzilarginase is Effective in Sustainably Lowering Plasma Arginine Levels Clinically Significant Improvements After Eight Doses Included Effects on Mobility and Adaptive Behavior Company to Host...
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
October 10, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
Company to Host Clinical Update Conference Call on October 17 at 8:30 a.m. ET Aeglea to Present Literature Review on Arginase 1 Deficiency Positive Preclinical Efficacy Data on its AEB4104...
FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency
October 01, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
Aeglea Eligible to Receive a Priority Review Voucher Company Plans to Initiate Pivotal Trial in First Half of 2019 AUSTIN, Texas, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc....
Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
September 17, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics...
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
September 04, 2018 07:00 ET
|
Aeglea BioTherapeutics, Inc.
Exceeded Enrollment Target with 15 Patients in Phase 1/2 Trial Additional Interim Data to be Presented at ASHG Conference in October 2018 Company Plans to Announce Pivotal Trial Design in Q4 2018...
Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference
August 28, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium
August 27, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
August 09, 2018 08:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...
Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule
July 30, 2018 16:00 ET
|
Aeglea BioTherapeutics, Inc.
Company Will Provide New Interim Data for Pegzilarginase in Patients with Arginase 1 Deficiency Preclinical Efficacy Data of AEB4104 - a New Enzyme Approach - for the treatment of Homocystinuria ...
Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer
July 19, 2018 16:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, July 19, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for...